CL2021001720A1 - Inhibidores de il-17a - Google Patents

Inhibidores de il-17a

Info

Publication number
CL2021001720A1
CL2021001720A1 CL2021001720A CL2021001720A CL2021001720A1 CL 2021001720 A1 CL2021001720 A1 CL 2021001720A1 CL 2021001720 A CL2021001720 A CL 2021001720A CL 2021001720 A CL2021001720 A CL 2021001720A CL 2021001720 A1 CL2021001720 A1 CL 2021001720A1
Authority
CL
Chile
Prior art keywords
inhibitors
formula
difluorocyclohexylimidazopyridazinyl
il17a
psoriasis
Prior art date
Application number
CL2021001720A
Other languages
English (en)
Inventor
David Andrew Coates
Brian Morgan Watson
Michael Enrico Richett
Kwame Frimpong
William Glen Holloway
Spencer Brian Jones
Adam Marc Levinson
Charles Willis Lugar Iii
Michael Edward Woodman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2021001720A1 publication Critical patent/CL2021001720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona ciertos compuestos de difluorociclohexilimidazopiridazinil-imidazolidinona de Fórmula II como inhibidores de IL17A, composiciones farmacéuticas de estos, y métodos para usar un compuesto de la Fórmula II para tratar ciertos síntomas de psoriasis, artritis reumatoide o esclerosis múltiple.
CL2021001720A 2019-01-07 2021-06-25 Inhibidores de il-17a CL2021001720A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789247P 2019-01-07 2019-01-07
US201962842770P 2019-05-03 2019-05-03

Publications (1)

Publication Number Publication Date
CL2021001720A1 true CL2021001720A1 (es) 2022-01-21

Family

ID=69423406

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001720A CL2021001720A1 (es) 2019-01-07 2021-06-25 Inhibidores de il-17a

Country Status (25)

Country Link
US (1) US12252491B2 (es)
EP (1) EP3908585B1 (es)
JP (1) JP7291226B2 (es)
KR (1) KR102600451B1 (es)
CN (1) CN113286795B (es)
AU (1) AU2020207196B2 (es)
BR (1) BR112021011095B1 (es)
CA (1) CA3125788C (es)
CL (1) CL2021001720A1 (es)
CO (1) CO2021008776A2 (es)
CR (1) CR20210357A (es)
DO (1) DOP2021000132A (es)
EC (1) ECSP21050201A (es)
ES (1) ES2977743T3 (es)
IL (1) IL284228B2 (es)
JO (1) JOP20210179A1 (es)
MA (1) MA54696A (es)
MX (1) MX2021008176A (es)
NZ (1) NZ777806A (es)
PE (1) PE20212304A1 (es)
PH (1) PH12021551632A1 (es)
SA (1) SA521422452B1 (es)
SG (1) SG11202105776WA (es)
TW (2) TWI752400B (es)
WO (1) WO2020146194A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202106444WA (en) 2018-12-19 2021-07-29 Leo Pharma As Amino-acid anilides as small molecule modulators of il-17
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
PE20230469A1 (es) 2020-04-30 2023-03-14 Janssen Pharmaceutica Nv Imidazopiridazinas como moduladores de il-17
BR112022025028A2 (pt) 2020-06-12 2023-01-31 Leo Pharma As Moduladores de molécula pequena de il-17
WO2021255086A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
WO2021255085A1 (en) 2020-06-18 2021-12-23 Leo Pharma A/S Small molecule modulators of il-17
EP4168400A1 (en) 2020-06-18 2023-04-26 LEO Pharma A/S Small molecule modulators of il-17
EP3943495A1 (en) 2020-07-24 2022-01-26 Leo Pharma A/S Small molecule modulators of il-17
CN113999234B (zh) * 2020-07-28 2023-03-07 成都先导药物开发股份有限公司 一种免疫调节剂
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
US20230399328A1 (en) 2020-11-09 2023-12-14 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
EP4259631A1 (en) 2020-12-14 2023-10-18 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
AR126255A1 (es) 2021-07-01 2023-10-04 UCB Biopharma SRL Derivados de imidazotriazina como moduladores de il-17
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
IL311751A (en) 2021-09-27 2024-05-01 Janssen Pharmaceutica Nv IL-17 imidazopyridazine inhibitory compounds
KR20240082371A (ko) * 2021-09-27 2024-06-10 얀센 파마슈티카 엔브이 이미다조피리다진 il-17 억제제 화합물
TW202413363A (zh) * 2021-11-04 2024-04-01 大陸商西藏海思科製藥有限公司 一種可抑制il-17a之雜環化合物及其用途
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
CN114736104B (zh) * 2022-04-20 2024-04-19 上海恩氟佳科技有限公司 一种二氟乙醛缩半乙醇的合成方法
KR20250023378A (ko) * 2022-05-19 2025-02-18 다이스 알파, 인크. 락탐 치환된 이미다조피리다진 il-17a 조정제 및 그의 용도
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2024138286A1 (en) * 2022-12-26 2024-07-04 Usynova Pharmaceuticals, Ltd. Il-17a modulators
CN120731202A (zh) * 2023-01-30 2025-09-30 戴斯阿尔法公司 基于苯并咪唑和氮杂-苯并咪唑的il-17a调节剂及其用途
PE20252337A1 (es) * 2023-02-13 2025-10-02 Dice Alpha Inc Moduladores de il-17a de imidazotriazina y usos de estos
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof
WO2025133234A1 (en) 2023-12-22 2025-06-26 Draupnir Bio Aps Sortilin binders and bifunctional compounds thereof
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026039170A1 (en) 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039167A1 (en) 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039172A1 (en) 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039171A1 (en) 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026039168A1 (en) 2024-08-12 2026-02-19 Dice Alpha, Inc. Il-17a inhibitors
WO2026073936A1 (en) * 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702213D0 (en) * 1996-02-24 1997-03-26 Zeneca Ltd Chemical compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007104696A1 (en) * 2006-03-15 2007-09-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antimalarial agents having polyaromatic structure
KR20090087027A (ko) * 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2892899B1 (en) * 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
WO2016037171A1 (en) 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoid il-17a inhibitors
JP7074674B2 (ja) 2015-09-23 2022-05-24 リアタ ファーマシューティカルズ インコーポレイテッド Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体
US10479793B2 (en) * 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
US11472794B2 (en) 2018-01-15 2022-10-18 UCB Biopharma SRL Fused imidazole derivatives as IL-17 modulators
CN110511213B (zh) 2018-05-22 2021-10-19 成都先导药物开发股份有限公司 一种免疫调节剂
SG11202106444WA (en) 2018-12-19 2021-07-29 Leo Pharma As Amino-acid anilides as small molecule modulators of il-17
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途

Also Published As

Publication number Publication date
EP3908585A1 (en) 2021-11-17
SG11202105776WA (en) 2021-06-29
DOP2021000132A (es) 2021-07-22
PH12021551632A1 (en) 2022-06-06
MX2021008176A (es) 2021-10-13
JP2022516654A (ja) 2022-03-01
PE20212304A1 (es) 2021-12-10
IL284228B2 (en) 2024-05-01
MA54696A (fr) 2022-04-13
ECSP21050201A (es) 2021-08-31
US20220073526A1 (en) 2022-03-10
CA3125788C (en) 2023-10-31
EP3908585B1 (en) 2024-03-06
SA521422452B1 (ar) 2023-12-05
JOP20210179A1 (ar) 2023-01-30
AU2020207196A1 (en) 2021-06-17
JP7291226B2 (ja) 2023-06-14
TW202039505A (zh) 2020-11-01
BR112021011095A2 (pt) 2021-08-31
WO2020146194A1 (en) 2020-07-16
ES2977743T3 (es) 2024-08-29
IL284228A (en) 2021-08-31
CA3125788A1 (en) 2020-07-16
CN113286795A (zh) 2021-08-20
CN113286795B (zh) 2023-11-03
AU2020207196B2 (en) 2022-03-17
KR102600451B1 (ko) 2023-11-10
NZ777806A (en) 2024-11-29
BR112021011095B1 (pt) 2023-11-28
KR20210100143A (ko) 2021-08-13
IL284228B1 (en) 2024-01-01
TW202214648A (zh) 2022-04-16
TWI752400B (zh) 2022-01-11
CR20210357A (es) 2021-09-01
US12252491B2 (en) 2025-03-18
CO2021008776A2 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
CL2021001720A1 (es) Inhibidores de il-17a
CO2020013865A2 (es) Análogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
MX388751B (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
EA201992584A1 (ru) Новые ингибиторы map4k1
CO2018008173A2 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
CU24643B1 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
PH12022550472A1 (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
EA201890072A1 (ru) Новые соединения в качестве модуляторов ror-гамма
PY1983118A (es) Inhibidores de pde4 que contienen boro
MX383520B (es) Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
EP4706394A3 (en) Use of alkoxypyrazoles as nitrification inhibitors
SA521421262B1 (ar) مشتق أمين جديد حلقي غير متجانس وتركيبة صيدلانية تشتمل عليه
SA521430909B1 (ar) B تركيبة علف تتضمن مركب سداسي هيدرو حامضى ومركبات وتطبيق منها
MX2023008634A (es) Análogos de rapamicina y usos de estos.
BR112022011572A2 (pt) Análogos de cistina diamida para cistinúria
AR122141A1 (es) Inhibidor de trka
MX2022001167A (es) Metodo para el tratamiento de una composicion que comprende vainillina natural.
EA202191464A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ИНГИБИТОРЫ IL-17A
DOP2020000103A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
CL2021001567A1 (es) Reactor de estanque para recuperación de metales